Ulka Vaishampayan, MD, FASCO

 labcoat
Beverly S Mitchell M.D.
Research Professor of Cancer Research and Clinical Professor of Internal Medicine
Medical School
Michigan Medicine
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
[email protected]
Available to mentor
Ulka Vaishampayan, MD, FASCO
labcoat
Clinical Professor
  • About
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program and co-leader of the Translational and Clinical Research Program at the University of Michigan Rogel Cancer Center, Ann Arbor MI. She is also the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. She is the PI of the Kidney Cancer Research Consortium grant awarded by the Dept of Defense. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development and biomarkers. She has authored or coauthored numerous publications focusing on novel therapeutics for patients with genitourinary malignancies.

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    Kidney cancer
    Prostate cancer
    Novel drug development
    Biomarker development
    Cancer Screening

    Recent Publications

     See All Publications
    • Preprint
      Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)
      Vaishampayan U, Taylor JMG, Kilari D, Dorff T, Sokolava A, Huang Y, Palmbos P, Brown J, Tsung I, Caram M, Yentz S, Nazha B, Reichert Z, Alumkal J. 2026 Apr 24; Research Square, DOI:10.21203/rs.3.rs-9471666/v1
    • Journal Article
      Abstract CT130: Initial results from a phase 1 study of PHST001, a macrophage activating anti-CD24 antibody, in patients with advanced/metastatic solid tumors
      Champiat S, Vaishampayan U, Cecchini M, Dorigo O, El-Khoueiry A, Fleming G, Mettu N, Dennis MJ, Davis E, Luebbe S, Cao J, Maute R, Rousseau R, Papadopoulos K. Cancer Research, 2026 Apr 19; 86 (8_Supplement): ct130 - ct130. DOI:10.1158/1538-7445.am2026-ct130
    • Journal Article
      Abstract CT154: Clinical activity and safety of novel BRAF inhibitor plixorafenib (FORE8394) in BRAF V600-mutated advanced colorectal cancers (CRC)
      Yaeger R, Sharma S, Parikh A, Shepherd SP, Monga M, Jiang P, Jang J, Paz M, Tsai F, Vaishampayan U, Rodon J. Cancer Research, 2026 Apr 19; 86 (8_Supplement): ct154 - ct154. DOI:10.1158/1538-7445.am2026-ct154
    • Proceeding / Abstract / Poster
      Abstract 4743: Dual inhibition of PIKfyve and FASN reveals therapeutic potential in neuroendocrine prostate cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karaburk H, Bhattacharyya R, Yin Y, Cao X, Xue H, Li C, Wang Z, Miner S, Vaishampayan UN, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. Cancer Research, 2026 Apr 3; 86 (7_Supplement): 4743 - 4743. DOI:10.1158/1538-7445.am2026-4743
    • Proceeding / Abstract / Poster
      Abstract 4743: Dual inhibition of PIKfyve and FASN reveals therapeutic potential in neuroendocrine prostate cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karaburk H, Bhattacharyya R, Yin Y, Cao X, Xue H, Li C, Wang Z, Miner S, Vaishampayan UN, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. Cancer Research, 2026 Apr 3; 86 (7_Supplement): 4743 - 4743. DOI:10.1158/1538-7445.am2026-4743
    • Journal Article
      A0594 Drug-testing in patient-derived renal cell carcinoma organoids reveals pathways of vulnerability and resistance
      Steven M, Nallandhighal S, Triner D, Duan Z, Knuth Z, Abusamra S, Dhanasekaran SM, Udager AM, Cotta BH, Su F, Madhi H, Kikuchi H, Hafez K, Singhal U, Kaffenberger S, Nagrath S, Chinnaiyan A, Morgan T, Zaslavsky A, Palapattu G, Vaishampayan U, Merrill N, Salami S. European Urology, 2026 Feb 15; 89: s1 - s2. DOI:10.1016/s0302-2838(26)00645-7
    • Proceeding / Abstract / Poster
      Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101
      Monda S, Nallandhighal S, Jaime-Casas S, Hafez K, Singhal U, Yentz SE, Morgan, MD TM, Kaffenberger S, Palapattu GS, Vaishampayan UN, Salami SS. Clinical Oncology, 2026 Mar 1; 44 (544):
    • Proceeding / Abstract / Poster
      Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101
      Monda S, Nallandhighal S, Jaime-Casas S, Hafez K, Singhal U, Yentz SE, Morgan, MD TM, Kaffenberger S, Palapattu GS, Vaishampayan UN, Salami SS. Clinical Oncology, 2026 Mar 1; 44 (544):